North America Gene Therapy Market to 2032
Overview
The North America Gene Therapy Market is expected to reach a 18,927.51 USD Billion by 2032 and is projected to grow at a CAGR of 27.81% from 2025 to 2032.
Revenue, 2024 (USD Billion)
4,773.76
Forecast, 2032 (USD Billion)
18,927.51
CAGR, 2024 - 2032
27.81%
Report Coverage
North America
North America Gene Therapy Market 2018-2032 USD Billion
North America Gene Therapy Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 4,773.76 USD Billion
- Projected Market Size (2032): 18,927.51 USD Billion
- CAGR (2025-2032): 27.81%
Key Findings of North America Gene Therapy Market
- The North America Gene Therapy Market was valued at 4,773.76 USD Billion in 2024.
- The North America Gene Therapy Market is likely to grow at a CAGR of 27.81% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Viral Vector in Vector Segment accounted for the largest share of the market with a revenue of 3,718.05 USD Billion
- The fastest growing segment Oncological Disorders in Application Segment grew Fastest with a CAGR of 30.93% during the forecast period from 2024 to 2032.
North America Gene Therapy Market Scope
North America Gene Therapy Market Segmentation & Scope
Vector
- Non-Viral Vector
- Viral Vector
End User
- Others
- Research Institutes
- Hospitals
- Cancer Institutes
Application
- Other Diseases
- Neurological Disorders
- Rare Diseases
- Infectious Disease
- Cardiovascular Diseases
- Oncological Disorders
Method
- In-Vivo
- Ex-Vivo
North America Gene Therapy Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 4,773.76 USD Billion |
| Market Value in 2032 | 18,927.51 USD Billion |
| CAGR (2025-2032) | 27.81% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Vector,End User,Application,Method |
Regional Insights:
-
Leading Market (2024-2032): North America, leading in terms of revenue 4,773.76 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 3,768.31 USD Billion in 2024.
Segments and Scope
-
North America Gene Therapy Market to 2032, By Vector
- Viral Vector is the largest segment in North America Gene Therapy Market to 2032 with a revenue of 3,718.05 USD Billion in the year 2024.
- Viral Vector is the Fastest growing segment in North America Gene Therapy Market to 2032 with a Growth rate of 29.04 % in forecast period 2025-2032.
-
North America Gene Therapy Market to 2032, By End User
- Cancer Institutes is the largest segment in North America Gene Therapy Market to 2032 with a revenue of 2,097.72 USD Billion in the year 2024.
- Cancer Institutes is the Fastest growing segment in North America Gene Therapy Market to 2032 with a Growth rate of 29.64 % in forecast period 2025-2032.
-
North America Gene Therapy Market to 2032, By Application
- Oncological Disorders is the largest segment in North America Gene Therapy Market to 2032 with a revenue of 2,216.37 USD Billion in the year 2024.
- Oncological Disorders is the Fastest growing segment in North America Gene Therapy Market to 2032 with a Growth rate of 30.93 % in forecast period 2025-2032.
-
North America Gene Therapy Market to 2032, By Method
- Ex-Vivo is the largest segment in North America Gene Therapy Market to 2032 with a revenue of 3,631.66 USD Billion in the year 2024.
- Ex-Vivo is the Fastest growing segment in North America Gene Therapy Market to 2032 with a Growth rate of 29.02 % in forecast period 2025-2032.
North America Gene Therapy Market Company Share Analysis
| Company Name |
|
||
| Oxford Biomedica | |||
| Novartis AG | |||
| Kite Pharma Inc. | |||
| Biogen | |||
| Bristol-Myers Squibb Company | |||
North America Gene Therapy Market Geographical Sales Distribution, 2018-2032 USD Billion
North America Gene Therapy Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The North America Gene Therapy Market is segmented based on Segmentation Vector,End User,Application,Method.
North America Gene Therapy Market was valued at USD 4,773.76(Revenue in USD Billion) in 2021.
North America Gene Therapy Market is projected to grow at a CAGR of 27.81% during the forecast period of 2024 to 2032.
The Viral Vector segment is expected to dominate the North America Gene Therapy Market, holding a largest market share of 3,718.05 USD Billion in 2024
North America Gene Therapy Market Scope
North America Gene Therapy Market Segmentation & Scope
Vector
- Non-Viral Vector
- Viral Vector
End User
- Others
- Research Institutes
- Hospitals
- Cancer Institutes
Application
- Other Diseases
- Neurological Disorders
- Rare Diseases
- Infectious Disease
- Cardiovascular Diseases
- Oncological Disorders
Method
- In-Vivo
- Ex-Vivo
Frequently Asked Questions
The North America Gene Therapy Market is segmented based on Segmentation Vector,End User,Application,Method.
North America Gene Therapy Market was valued at USD 4,773.76(Revenue in USD Billion) in 2021.
North America Gene Therapy Market is projected to grow at a CAGR of 27.81% during the forecast period of 2024 to 2032.
The estimated market value of the North America Gene Therapy Market for final year is USD 18,927.51 (USD Billion).
North America Gene Therapy Market Company Profiling
Frequently Asked Questions
The North America Gene Therapy Market is segmented based on Segmentation Vector,End User,Application,Method.
North America Gene Therapy Market was valued at USD 4,773.76(Revenue in USD Billion) in 2021.
North America Gene Therapy Market is projected to grow at a CAGR of 27.81% during the forecast period of 2024 to 2032.
The estimated market value of the North America Gene Therapy Market for final year is USD 18,927.51 (USD Billion).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.